| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Address correspondence and reprint requests to Dr. Barry G.W. Arnason, University of Chicago, Department of Neurology, 5841 S. Maryland Ave., MC 2030, Chicago, IL 60637; e-mail: barnason{at}drugs.bsd.uchicago.edu
OBJECTIVE: A double-blind, placebo-controlled phase II study was conducted in 168 patients, most with relapsing-remitting MS, to evaluate whether lenercept would reduce new lesions on MRI.
BACKGROUND: Tumor necrosis factor (TNF) has been implicated in MS pathogenesis, has been identified in active MS lesions, is toxic to oligodendrocytes in vitro, and worsens the severity of experimental allergic encephalomyelitis (EAE) in animals. Lenercept, a recombinant TNF receptor p55 immunoglobulin fusion protein (sTNFR-IgG p55), protects against EAE.
METHODS: Patients received 10, 50, or 100 mg of lenercept or placebo IV every 4 weeks for up to 48 weeks. MRI scans and clinical evaluations were performed at screening, at baseline, and then every 4 weeks (immediately before dosing) through study week 24.
RESULTS: There were no significant differences between groups on any MRI study measure, but the number of lenercept-treated patients experiencing exacerbations was significantly increased compared with patients receiving placebo (p = 0.007) and their exacerbations occurred earlier (p = 0.006). Neurologic deficits tended to be more severe in the lenercept treatment groups, although this did not affect Expanded Disability Status Scale scores. Anti-lenercept antibodies were present in a substantial number of treated patients; serum lenercept trough concentrations were detectable in only a third. Adverse events that increased in frequency in treated patients included headache, nausea, abdominal pain, and hot flushes.
CONCLUSIONS: Lenercept failed to be beneficial, but insight into the role of TNF in MS exacerbations was gained.
This article has been cited by other articles:
|
|
 |
|
  C. L. Helliwell and A. J. Coles Monoclonal antibodies in multiple sclerosis treatment: current and future steps Therapeutic Advances in Neurological Disorders, July 1, 2009; 2(4): 195 - 203. [PDF]
|
|
|
|
 |
|
 H. Wiendl and R. Hohlfeld Multiple sclerosis therapeutics: Unexpected outcomes clouding undisputed successes Neurology, March 17, 2009; 72(11): 1008 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Jacob, H. Yang, L. Pricop, Y. Liu, X. Gao, S. G. Zheng, J. Wang, H.-X. Gao, C. Putterman, M. N. Koss, et al. Accelerated Pathological and Clinical Nephritis in Systemic Lupus Erythematosus-Prone New Zealand Mixed 2328 Mice Doubly Deficient in TNF Receptor 1 and TNF Receptor 2 via a Th17-Associated Pathway J. Immunol., February 15, 2009; 182(4): 2532 - 2541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Wekerle Lessons from multiple sclerosis: models, concepts, observations Ann Rheum Dis, December 1, 2008; 67(Suppl_3): iii56 - iii60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kumpfel, L-A Hoffmann, H. Pellkofer, W. Pollmann, W. Feneberg, R. Hohlfeld, and P. Lohse Multiple sclerosis and the TNFRSF1A R92Q mutation: Clinical characteristics of 21 cases Neurology, November 25, 2008; 71(22): 1812 - 1820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Notley, J. J. Inglis, S. Alzabin, F. E. McCann, K. E. McNamee, and R. O. Williams Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells J. Exp. Med., October 27, 2008; 205(11): 2491 - 2497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ban, J. Zhang, L. Wang, W. Kuhtreiber, D. Burger, and D. L. Faustman Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism PNAS, September 9, 2008; 105(36): 13644 - 13649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Novak, A. E. Lovett-Racke, and M. K. Racke Monoclonal Antibody Therapies and Neurologic Disorders Arch Neurol, September 1, 2008; 65(9): 1162 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dasgupta, J. Bayry, S. Andre, J. D. Dimitrov, S. V. Kaveri, and S. Lacroix-Desmazes Auditing Protein Therapeutics Management by Professional APCs: Toward Prevention of Immune Responses against Therapeutic Proteins J. Immunol., August 1, 2008; 181(3): 1609 - 1615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sriram TRAPS and MS: Two diseases or an MS mimic? Neurology, March 25, 2008; 70(13_Part_2): 1077 - 1078. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kumpfel, M. Schwan, Th. Pollmacher, A. Yassouridis, M. Uhr, C. Trenkwalder, and F. Weber Time of interferon-{beta} 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients Multiple Sclerosis, November 1, 2007; 13(9): 1138 - 1145. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Singh and M. Suresh A role for TNF in limiting the duration of CTL effector phase and magnitude of CD8 T cell memory J. Leukoc. Biol., November 1, 2007; 82(5): 1201 - 1211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Ehrenstein and C. Mauri If the treatment works, do we need to know why?: the promise of immunotherapy for experimental medicine J. Exp. Med., October 1, 2007; 204(10): 2249 - 2252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.R. Jeffery Failure of allogeneic bone marrow transplantation to arrest disease activity in multiple sclerosis Multiple Sclerosis, September 1, 2007; 13(8): 1071 - 1075. [Abstract] [PDF]
|
|
|
|
 |
|
 S. R. Plant, H. A. Iocca, Y. Wang, J. C. Thrash, B. P. O'Connor, H. A. Arnett, Y.-X. Fu, M. J. Carson, and J. P.-Y. Ting Lymphotoxin {beta} Receptor (Lt{beta}R): Dual Roles in Demyelination and Remyelination and Successful Therapeutic Intervention Using Lt{beta}R-Ig Protein J. Neurosci., July 11, 2007; 27(28): 7429 - 7437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Taoufik, S. Valable, G. J. Muller, M. L. Roberts, D. Divoux, A. Tinel, A. Voulgari-Kokota, V. Tseveleki, F. Altruda, H. Lassmann, et al. FLIPL Protects Neurons against In Vivo Ischemia and In Vitro Glucose Deprivation-Induced Cell Death J. Neurosci., June 20, 2007; 27(25): 6633 - 6646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S Zandi and A. J Coles Notes on the kidney and its diseases for the neurologist J. Neurol. Neurosurg. Psychiatry, May 1, 2007; 78(5): 444 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Choudry and J. W. Chan An Update on Monoclonal Antibody Therapies in Multiple Sclerosis Journal of Pharmacy Practice, April 1, 2007; 20(2): 167 - 180. [Abstract] [PDF]
|
|
|
|
|
|
M Andersson, E Svenungsson, M Khademi, J Lampa, L Brundin, and E Wallstrom No signs of immunoactivation in the cerebrospinal fluid during treatment with infliximab Ann Rheum Dis, September 1, 2006; 65(9): 1237 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Aktas, T. Prozorovski, and F. Zipp Death Ligands and Autoimmune Demyelination Neuroscientist, August 1, 2006; 12(4): 305 - 316. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Gold, C. Linington, and H. Lassmann Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research Brain, August 1, 2006; 129(8): 1953 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Friese, X. Montalban, N. Willcox, J. I. Bell, R. Martin, and L. Fugger The value of animal models for drug development in multiple sclerosis Brain, August 1, 2006; 129(8): 1940 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. I. Farukhi, K. Bollinger, P. Ruggieri, and M. S. Lee Infliximab-Associated Third Nerve Palsy Arch Ophthalmol, July 1, 2006; 124(7): 1055 - 1057. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Feldmann and C. D. Pusey Is There a Role for TNF-{alpha} in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis? Lessons from Other Chronic Inflammatory Diseases J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1243 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Gimenez, J. Sim, A. S. Archambault, R. S. Klein, and J. H. Russell A Tumor Necrosis Factor Receptor 1-Dependent Conversation between Central Nervous System-Specific T Cells and the Central Nervous System Is Required for Inflammatory Infiltration of the Spinal Cord Am. J. Pathol., April 1, 2006; 168(4): 1200 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Imitola, T. Chitnis, and S. J. Khoury Insights Into the Molecular Pathogenesis of Progression in Multiple Sclerosis: Potential Implications for Future Therapies Arch Neurol, January 1, 2006; 63(1): 25 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Noguera-Pons, J. Borras-Blasco, I. Romero-Crespo, R. Anton-Torres, A. Navarro-Ruiz, and J. A. Gonzalez-Ferrandez Optic Neuritis with Concurrent Etanercept and Isoniazid Therapy Ann. Pharmacother., December 1, 2005; 39(12): 2131 - 2134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Zajicek Diagnosis and disease modifying treatments in multiple sclerosis Postgrad. Med. J., September 1, 2005; 81(959): 556 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Friese and L. Fugger Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain, August 1, 2005; 128(8): 1747 - 1763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Suhler, J. R. Smith, M. S. Wertheim, A. K. Lauer, D. E. Kurz, T. D. Pickard, and J. T. Rosenbaum A Prospective Trial of Infliximab Therapy for Refractory Uveitis: Preliminary Safety and Efficacy Outcomes Arch Ophthalmol, July 1, 2005; 123(7): 903 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Titelbaum, A. Degenhardt, and R. P. Kinkel Anti-Tumor Necrosis Factor Alpha-Associated Multiple Sclerosis AJNR Am. J. Neuroradiol., June 1, 2005; 26(6): 1548 - 1550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E Walker, S. N Giri, and S. B Margolin A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis Multiple Sclerosis, April 1, 2005; 11(2): 149 - 158. [Abstract] [PDF]
|
|
|
|
|
|
D. R. Jeffery Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis Neurology, December 28, 2004; 63(12_suppl_6): S41 - S46. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. E. Peterson, S. Hughes, D. E. Dimcheff, K. Wehrly, and B. Chesebro Separate Sequences in a Murine Retroviral Envelope Protein Mediate Neuropathogenesis by Complementary Mechanisms with Differing Requirements for Tumor Necrosis Factor Alpha J. Virol., December 1, 2004; 78(23): 13104 - 13112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K L Hyrich, A J Silman, K D Watson, and D P M Symmons Anti-tumour necrosis factor {alpha} therapy in rheumatoid arthritis: an update on safety Ann Rheum Dis, December 1, 2004; 63(12): 1538 - 1543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. C. Singer, B. Otto, H. Steinmetz, and U. Ziemann Acute neuropathy with multiple conduction blocks after TNF{alpha} monoclonal antibody therapy Neurology, November 9, 2004; 63(9): 1754 - 1754. [Full Text] [PDF]
|
|
|
|
|
|
R. Hohlfeld and H. Wekerle Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines PNAS, October 5, 2004; 101(suppl_2): 14599 - 14606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Minden, E Aganna, M F McDermott, and A Zink Tumour necrosis factor receptor associated periodic syndrome (TRAPS) with central nervous system involvement Ann Rheum Dis, October 1, 2004; 63(10): 1356 - 1357. [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Olsen and C. M. Stein New Drugs for Rheumatoid Arthritis N. Engl. J. Med., May 20, 2004; 350(21): 2167 - 2179. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Y.C. Strong, B. C. Erny, H. Herzenberg, and K. J. Razzeca Retrobulbar Optic Neuritis Associated with Infliximab in a Patient with Crohn Disease Ann Intern Med, April 20, 2004; 140(8): W-34 - W-34. [Full Text] [PDF]
|
|
|
|
|
|
P. Flachenecker, I. Bihler, F Weber, M Gottschalk, K. V Toyka, and P. Rieckmann Cytokine mRNA expression in patients with multiple sclerosis and fatigue Multiple Sclerosis, April 1, 2004; 10(2): 165 - 169. [Abstract] [PDF]
|
|
|
|
|
|
H. A. Arnett, Y. Wang, G. K. Matsushima, K. Suzuki, and J. P.-Y. Ting Functional Genomic Analysis of Remyelination Reveals Importance of Inflammation in Oligodendrocyte Regeneration J. Neurosci., October 29, 2003; 23(30): 9824 - 9832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schmidt, J. M. Metselaar, and R. Gold Intravenous Liposomal Prednisolone Downregulates In Situ TNF-{alpha} Production by T-cells in Experimental Autoimmune Encephalomyelitis J. Histochem. Cytochem., September 1, 2003; 51(9): 1241 - 1244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sturzebecher, K. P. Wandinger, A. Rosenwald, M. Sathyamoorthy, A. Tzou, P. Mattar, J. A. Frank, L. Staudt, R. Martin, and H. F. McFarland Expression profiling identifies responder and non-responder phenotypes to interferon-{beta} in multiple sclerosis Brain, June 1, 2003; 126(6): 1419 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A B Gottlieb Clinical research helps elucidate the role of tumor necrosis factor-{alpha}in the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes Lupus, March 1, 2003; 12(3): 190 - 194. [Abstract] [PDF]
|
|
|
|
|
|
T Seifert, B C Kieseier, S Ropele, S Strasser-Fuchs, F Quehenberger, F Fazekas, and H-P Hartung TACE mRNA expression in peripheral mononuclear cells precedes new lesions on MRI in multiple sclerosis Multiple Sclerosis, December 1, 2002; 8(6): 447 - 451. [Abstract] [PDF]
|
|
|
|
|
|
V Ozenci, M Kouwenhoven, and H Link Cytokines in multiple sclerosis: methodological aspects and pathogenic implications Multiple Sclerosis, October 1, 2002; 8(5): 396 - 404. [Abstract] [PDF]
|
|
|
|
|
|
R. Foroozan, L. M. Buono, R. C. Sergott, and P. J. Savino Retrobulbar Optic Neuritis Associated With Infliximab Arch Ophthalmol, July 1, 2002; 120(7): 985 - 987. [Full Text] [PDF]
|
|
|
|
|
|
N. L. Sicotte and R. R. Voskuhl Onset of multiple sclerosis associated with anti-TNF therapy Neurology, November 27, 2001; 57(10): 1885 - 1888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Steinman Blockade of gamma interferon might be beneficial in MS Multiple Sclerosis, October 1, 2001; 7(5): 275 - 276. [PDF]
|
|
|
|
|
|
S Skurkovich, A Boiko, I Beliaeva, A Buglak, T Alekseeva, N Smirnova, O Kulakova, V Tchechonin, O Gurova, T Deomina, et al. Randomized study of antibodies to IFN-g and TNF-a in secondary progressive multiple sclerosis Multiple Sclerosis, October 1, 2001; 7(5): 277 - 284. [Abstract] [PDF]
|
|
|
|
|
|
J. E Walker and S. B Margolin Pirfenidone for chronic progressive multiple sclerosis Multiple Sclerosis, October 1, 2001; 7(5): 305 - 312. [Abstract] [PDF]
|
|
|
|
|
|
L. Steinman Gene microarrays and experimental demyelinating disease: a tool to enhance serendipity Brain, October 1, 2001; 124(10): 1897 - 1899. [Full Text] [PDF]
|
|
|
|
|
|
E. S. Huseby, D. Liggitt, T. Brabb, B. Schnabel, C. Ohlen, and J. Goverman A Pathogenic Role for Myelin-Specific Cd8+ T Cells in a Model for Multiple Sclerosis J. Exp. Med., September 3, 2001; 194(5): 669 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Steinman Myelin-Specific Cd8 T Cells in the Pathogenesis of Experimental Allergic Encephalitis and Multiple Sclerosis J. Exp. Med., September 3, 2001; 194(5): f27 - f30. [Full Text] [PDF]
|
|
|
|
|
|
R. Furlan, E. Brambilla, F. Ruffini, P. L. Poliani, A. Bergami, P. C. Marconi, D. M. Franciotta, G. Penna, G. Comi, L. Adorini, et al. Intrathecal Delivery of IFN-{gamma} Protects C57BL/6 Mice from Chronic-Progressive Experimental Autoimmune Encephalomyelitis by Increasing Apoptosis of Central Nervous System-Infiltrating Lymphocytes J. Immunol., August 1, 2001; 167(3): 1821 - 1829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kamradt and N. A. Mitchison Tolerance and Autoimmunity N. Engl. J. Med., March 1, 2001; 344(9): 655 - 664. [Full Text] [PDF]
|
|
|
|
|
|
J. H. Klippel Biologic Therapy for Rheumatoid Arthritis N. Engl. J. Med., November 30, 2000; 343(22): 1640 - 1641. [Full Text]
|
|
|
|
|
|
K. W Selmaj Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system Ann Rheum Dis, November 1, 2000; 59(90001): i94 - 102. [Full Text] [PDF]
|
|
|
|
|
|
J. H. Noseworthy, C. Lucchinetti, M. Rodriguez, and B. G. Weinshenker Multiple Sclerosis N. Engl. J. Med., September 28, 2000; 343(13): 938 - 952. [Full Text] [PDF]
|
|
|
|
|
|
S. R. Schwid and J. L. Trotter Lessons from linomide: A failed trial, but not a failure Neurology, May 9, 2000; 54(9): 1716 - 1717. [Full Text] [PDF]
|
|
|
|
|
|
S. R. Schwid and J. H. Noseworthy Targeting immunotherapy in multiple sclerosis Neurology, August 1, 1999; 53(3): 444 - 444. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
